Clinical Trials Logo

Autistic Disorder clinical trials

View clinical trials related to Autistic Disorder.

Filter by:

NCT ID: NCT03206996 Completed - Clinical trials for Autism Spectrum Disorder

Exposure Therapy for Auditory Sensitivity in Autism

Start date: September 30, 2017
Phase: N/A
Study type: Interventional

Auditory hyper-reactivity affects up to 66% of children with autism spectrum disorder (ASD) and has been linked to greater stress and anxiety for children and their families. Exposure and Response Prevention (E/RP) is highly effective for reducing obsessive/compulsive behaviors in children with both OCD and ASD. This study is the first to assess the feasibility and efficacy of E/RP for auditory sensory hyper-reactivity in ASD.

NCT ID: NCT03204786 Completed - Clinical trials for Autism Spectrum Disorder

Intranasal Vasopressin Treatment in Children With Autism

Start date: February 20, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this clinical trial is to investigate the effectiveness of vasopressin nasal spray for treating symptoms associated with autism. Vasopressin is a hormone that is produced naturally within the body and has been implicated in regulating social behaviors. It has been proposed that administration of the hormone may also help improve social functioning in individuals with autism.

NCT ID: NCT03202303 Recruiting - Clinical trials for Autism Spectrum Disorder

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

Start date: April 12, 2019
Phase: Phase 2
Study type: Interventional

This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.

NCT ID: NCT03197922 Completed - Clinical trials for Autism Spectrum Disorder

Treatment of Encopresis in Children With Autism Spectrum Disorders

Start date: October 25, 2017
Phase: Phase 3
Study type: Interventional

This study is comparing a multidisciplinary intervention for encopresis (MIE), consisting of both medical and behavioral components to treatment as usual control (TAU). Participants are first screened by a pediatric gastroenterologist and assessed and treated for any constipation or other potential medical complications. Following this, caregivers collect data on bowel movements and continence during a home baseline lasting no less than 14 days and no more than 21 days. Participants randomly assigned to treatment as usual or the treatment group, and begin attending daily appointments in clinic for 2 weeks. At appointments, the behavior team implements structured sits on the toilet to promote independent bowel movements (BMs). If an independent BM does not occur, the study team will administer a suppository to promote rapid release of the bowels and prompt the child to remain on the toilet following administration. In doing so, continent bowel movements are predictably evoked while the child is on the toilet, allowing for reinforcement with praise and preferred toys/activities. Eventually, suppositories are gradually decreased until the child is having BMs independently. Caregivers are trained to continue implementing the intervention following the clinic-based portion. The purpose of the current study is to evaluate MIE using a large randomized clinical trial (RCT), addressing the Department of Defense Autism Research Program, Area of Interest of Therapies to Alleviate Conditions Co-Occurring with autism spectrum disorder (ASD). The researchers will recruit 112 children diagnosed with ASD, randomizing them to two weeks of MIE, or treatment as usual (TAU) consisting of behavioral consultation and medical intervention. This study will evaluate MIE compared to TAU and determine the optimal treatment length.

NCT ID: NCT03196713 Completed - Clinical trials for Autism Spectrum Disorder

Early Intervention, Supervision, Quality and Outcome in ASD

Start date: April 1, 2013
Phase: N/A
Study type: Interventional

The objective of this study is to examine the significance of knowledge of autism spectrum disorder (ASD), and early intensive behavioral intervention, as well as trust in EIBI, adequate assessment of EIBI quality, and EIBI supervision on EIBI intervention outcome in ASD.

NCT ID: NCT03195465 Terminated - Clinical trials for Autism Spectrum Disorder

The Effect of High Antioxidant Cacao on Behaviors in Children With Autism Spectrum Disorder

Start date: November 14, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if routine consumption of high antioxidant cacao can have an effect on the behaviors of children with Autism Spectrum Disorder. This is proposed as children with Autism Spectrum Disorder have elevated oxidative stress markers, such as, free radicals making them highly vulnerable to oxidative damage. Thus, it is proposed that foods high in antioxidant activity can offer protection against oxidative stress and thus impact behaviors.

NCT ID: NCT03195244 Completed - Clinical trials for Autism Spectrum Disorder

Aquatic Therapy and Autism Spectrum Disorders

AT&ASD
Start date: June 12, 2017
Phase: N/A
Study type: Interventional

To compare the efficacy of one-on-one versus group-based aquatic therapy on the social interactions, behaviors and physical activities of children with autism spectrum disorders (ASDs).

NCT ID: NCT03183674 Completed - Autistic Disorder Clinical Trials

Oxytocin in Spectrum Autism Disorders

OxytocinASD
Start date: July 15, 2016
Phase: Phase 1
Study type: Interventional

Observe effects of oxytocin on individuals with autism spectrum disorder

NCT ID: NCT03180112 Not yet recruiting - Clinical trials for Autism Spectrum Disorder

The Association Between Herpes Simplex Viruses and Autism

Start date: August 1, 2017
Phase: N/A
Study type: Observational

Autism spectrum disorders are pervasive developmental disorders that include autistic disorder, Asperger's disorder, and pervasive developmental disorder-not otherwise specified.They are characterized by stereotypic behaviors, variable deficits in language and social skills and a wide range of other behavioral problems. Autism spectrum disorders manifest during childhood and at least thirty percent present with sudden clinical regression of development around three years of age.

NCT ID: NCT03179787 Completed - Autism Clinical Trials

Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism

Start date: April 1, 2017
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety and effectiveness of aripiprazole in patients with autism in the real world clinical setting in Japan.